Towa Pharmaceutical Co., Ltd.
4553.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥131,873,775 | ¥139,295,430 | ¥93,275,411 | ¥135,244,601 |
| - Cash | ¥45,471,000 | ¥29,650,000 | ¥24,257,000 | ¥32,830,000 |
| + Debt | ¥232,366,000 | ¥202,356,000 | ¥173,065,000 | ¥144,128,000 |
| Enterprise Value | ¥318,768,775 | ¥312,001,430 | ¥242,083,411 | ¥246,542,601 |
| Revenue | ¥259,594,000 | ¥227,934,000 | ¥208,859,000 | ¥165,615,000 |
| % Growth | 13.9% | 9.1% | 26.1% | – |
| Gross Profit | ¥94,729,000 | ¥81,383,000 | ¥72,714,000 | ¥70,186,000 |
| % Margin | 36.5% | 35.7% | 34.8% | 42.4% |
| EBITDA | ¥48,055,000 | ¥35,536,000 | ¥25,143,000 | ¥29,492,000 |
| % Margin | 18.5% | 15.6% | 12% | 17.8% |
| Net Income | ¥18,986,000 | ¥16,173,000 | ¥2,201,000 | ¥15,914,000 |
| % Margin | 7.3% | 7.1% | 1.1% | 9.6% |
| EPS Diluted | 385.7 | 328.58 | 44.72 | 316.19 |
| % Growth | 17.4% | 634.7% | -85.9% | – |
| Operating Cash Flow | ¥23,401,000 | ¥8,212,000 | ¥2,544,000 | ¥22,129,000 |
| Capital Expenditures | -¥28,736,000 | -¥39,325,000 | -¥30,469,000 | -¥13,576,000 |
| Free Cash Flow | -¥5,335,000 | -¥31,113,000 | -¥27,925,000 | ¥8,553,000 |